Tasso

Executive Summary

Tasso is a Seattle-based medical device company founded in 2013 that has developed a virtually painless, at-home blood collection device designed to replace traditional venipuncture and fingersticks. The company's mission is to enable diagnostic testing in the home, improving patient experience and facilitating more informed healthcare decisions. Tasso's technology leverages a small, wearable device that collects capillary blood from the upper arm, which is then mailed to a lab for analysis. This approach eliminates the need for clinic visits and reduces patient discomfort, addressing key barriers to routine blood testing. The company has secured multiple patents and regulatory clearances, including FDA 510(k) clearance for its Tasso+ device, and has formed partnerships with major diagnostic laboratories and healthcare organizations to expand access to home-based testing.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Next-Generation Device (e.g., Tasso-M20 or pediatric version)70% success
• Q2 2026Major Partnership or Commercial Agreement with National Lab Chain60% success
• Q4 2026Series D or Later Funding Round with Strategic Investor55% success